Trial
NCT03871829
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Multiple Myeloma
Intervention
Carfilzomib 20 mg/m^2
Why stopped
The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee recommendation was early stop of the study for futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-30